Trial Profile
A Study to Evaluate the Clinical Experience with Alemtuzumab Infusion Strategies and Infusion-Associated Reactions (IARs) at the Infusion Site
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Graft-versus-host disease; Multiple sclerosis; T-cell prolymphocytic leukaemia
- Focus Adverse reactions
- 18 Feb 2016 New trial record